{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:33:45Z","timestamp":1771234425831,"version":"3.50.1"},"reference-count":126,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EU Horizon Health","award":["101136582"],"award-info":[{"award-number":["101136582"]}]},{"name":"Innovation Health Initiative Joint Undertaking","award":["101194780"],"award-info":[{"award-number":["101194780"]}]},{"name":"EU Horizon Europe Program","award":["101095470"],"award-info":[{"award-number":["101095470"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Interleukin-23 (IL-23) is a pivotal cytokine driving intestinal inflammation in inflammatory bowel disease (IBD). The development of monoclonal antibodies selectively targeting the p19 subunit of IL-23, including risankizumab, mirikizumab and guselkumab, has significantly expanded the therapeutic landscape of IBD. Landmark phase 3 trials in Crohn\u2019s disease (CD) and ulcerative colitis (UC) have demonstrated high efficacy and durable responses, followed by recent regulatory approvals across both indications. Notably, the SEQUENCE trial established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of IL-23p19 blockade and its differentiation from prior p40 inhibition. With additional agents in advanced development, IL-23p19 inhibitors are now emerging as a bona fide treatment class in IBD. Furthermore, IL-23p19 inhibitors display favorable safety profiles and convenient subcutaneous administration regimens, which broaden their applicability across diverse patient populations. However, key knowledge gaps remain regarding optimal treatment positioning, comparative effectiveness, and long-term disease outcomes. Precision medicine approaches will be crucial to fully exploit the potential of this drug class. For instance, early biomarkers can help monitor response, while future integration of serological and multi-omics biomarkers may enable the prediction of treatment success and guide personalized selection. This review summarizes the current knowledge base regarding IL-23p19 inhibitors in IBD, highlights their class effects and unique clinical value, and outlines a research agenda towards biomarker-driven and precision-guided use. Ultimately, IL-23p19-inhibition exemplifies how targeted immunotherapy and precision medicine can converge in order to reshape IBD management.<\/jats:p>","DOI":"10.3390\/jpm16020119","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:38:39Z","timestamp":1771231119000},"page":"119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions"],"prefix":"10.3390","volume":"16","author":[{"given":"Ilse A.","family":"Pool","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8168-5694","authenticated-orcid":false,"given":"Antonius T.","family":"Otten","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-765X","authenticated-orcid":false,"given":"Jos G. W.","family":"Kosterink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"PharmacoTherapy, Epidemiology & Economics, Groningen Research Institute of Pharmacy, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4563-7462","authenticated-orcid":false,"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-1201","authenticated-orcid":false,"given":"Paola","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"Pharmacometrics Expertise Center of the Northern Netherlands, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"Department of Pediatrics, Beatrix Children\u2019s Hospital, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"Department of Pharmaceutical, Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-3821","authenticated-orcid":false,"given":"Arno R.","family":"Bourgonje","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands"},{"name":"The Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, 10029 NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: Current State of the Art","volume":"13","author":"Fiocchi","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Caballero Mateos, A.M., Ca\u00f1adas de la Fuente, G.A., and Gros, B. (2025). Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051536"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing Anti-TNF Treatments in Inflammatory Bowel Disease","volume":"13","author":"Kopylov","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic Review with Meta-Analysis: Real-World Effectiveness and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alipour, O., Gualti, A., Shao, L., and Zhang, B. (2021). Systematic Review and Meta-Analysis: Real-World Data Rates of Deep Remission with Anti-TNF\u03b1 in Inflammatory Bowel Disease. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01883-6"},{"key":"ref_6","unstructured":"(2025, September 10). An Induction Study of Mirikizumab in Participants with Moderately to Severely Active Ulcerative Colitis (LUCENT 1), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT03518086?term=NCT03518086&rank=1."},{"key":"ref_7","unstructured":"(2025, September 10). A Maintenance Study of Mirikizumab in Participants with Moderately to Severely Active Ulcerative Colitis (LUCENT 2), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT03524092?term=NCT03524092&rank=1."},{"key":"ref_8","unstructured":"(2025, September 10). A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03158285."},{"key":"ref_9","unstructured":"(2025, September 10). A Study of Guselkumab in the Treatment of Participants with Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02207231."},{"key":"ref_10","unstructured":"(2025, October 16). A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn\u2019s Disease (GALAXI), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03466411."},{"key":"ref_11","unstructured":"(2025, September 10). A Study of Guselkumab in the Treatment of Participants with Moderate to Severe Plaque-Type Psoriasis with Randomized Withdrawal and Retreatment (VOYAGE 2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02207244."},{"key":"ref_12","unstructured":"(2025, September 10). A Study of the Efficacy and Safety of Risankizumab in Participants with Crohn\u2019s Disease (FORTIFY), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03105102."},{"key":"ref_13","unstructured":"(2025, September 10). A Study to Assess the Efficacy and Safety of Risankizumab in Participants with Ulcerative Colitis (COMMAND), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03398135."},{"key":"ref_14","unstructured":"(2025, September 10). A Study of the Efficacy and Safety of Risankizumab in Participants with Moderately to Severely Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03105128."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjac034","article-title":"Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention","volume":"16","author":"Sewell","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14712598.2024.2401148","article-title":"The Immunologic Role of IL-23 in Psoriatic Arthritis: A Potential Therapeutic Target","volume":"24","author":"Su","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Audia, S., Brescia, C., Dattilo, V., Torchia, N., Trapasso, F., and Amato, R. (2024). The IL-23R and Its Genetic Variants: A Hitherto Unforeseen Bridge Between the Immune System and Cancer Development. Cancers, 17.","DOI":"10.3390\/cancers17010055"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Deng, Z., Wang, S., Wu, C., and Wang, C. (2023). IL-17 Inhibitor-Associated Inflammatory Bowel Disease: A Study Based on Literature and Database Analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1124628"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction Therapy with the Selective Interleukin-23 Inhibitor Risankizumab in Patients with Moderate-to-Severe Crohn\u2019s Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as Induction Therapy for Crohn\u2019s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials","volume":"399","author":"Panaccione","year":"2022","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as Maintenance Therapy for Moderately to Severely Active Crohn\u2019s Disease: Results from the Multicentre, Randomised, Double-Blind, Placebo-Controlled, Withdrawal Phase 3 FORTIFY Maintenance Trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"jjaf005","DOI":"10.1093\/ecco-jcc\/jjaf005","article-title":"Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies","volume":"19","author":"Panaccione","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for Ulcerative Colitis","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"ref_25","first-page":"9","article-title":"Risankizumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study","volume":"19","author":"Pbo","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","article-title":"Efficacy and Safety of Intravenous Induction and Subcutaneous Maintenance Therapy with Guselkumab for Patients with Crohn\u2019s Disease (GALAXI-2 and GALAXI-3): 48-Week Results from Two Phase 3, Randomised, Placebo and Active Comparator-Controlled, Double-Blind, Triple-Dummy Trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the Treatment of Crohn\u2019s Disease: Induction Results from the Phase 2 GALAXI-1 Study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and Safety of 48 Weeks of Guselkumab for Patients with Crohn\u2019s Disease: Maintenance Results from the Phase 2, Randomised, Double-Blind GALAXI-1 Trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study","volume":"165","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis (QUASAR): Phase 3 Double-Blind, Randomised, Placebo-Controlled Induction and Maintenance Studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn\u2019s Disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and Safety of Mirikizumab in Patients with Moderately-to-Severely Active Crohn\u2019s Disease: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Treat-through Study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"Dubinsky","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/ibd\/izae024","article-title":"Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"114076","DOI":"10.1016\/j.addr.2021.114076","article-title":"Clinical Translation of Advanced Colonic Drug Delivery Technologies","volume":"181","author":"Awad","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2501635122","DOI":"10.1073\/pnas.2501635122","article-title":"Engineering a Protease-Stable, Oral Single-Domain Antibody to Inhibit IL-23 Signaling","volume":"122","author":"Ota","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1016\/j.cell.2024.05.052","article-title":"Preclinical Proof of Principle for Orally Delivered Th17 Antagonist Miniproteins","volume":"187","author":"Berger","year":"2024","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"19422","DOI":"10.1038\/s41598-021-97236-0","article-title":"Preclinical Development of a Bispecific TNF\u03b1\/IL-23 Neutralising Domain Antibody as a Novel Oral Treatment for Inflammatory Bowel Disease","volume":"11","author":"Roberts","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S2468-1253(25)00296-1","article-title":"Safety and Pharmacokinetics of SOR102, an Oral Bispecific Inhibitor of TNF and Interleukin-23 in Healthy Participants and Patients with Ulcerative Colitis: A First-in-Human, Double-Blind, Randomised, Placebo-Controlled, Phase 1 Trial","volume":"11","author":"Jairath","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.14309\/01.ajg.0000592540.43886.35","article-title":"Safety, Tolerability, and Pharmacokinetics of PTG-200, an Oral GI-Restricted Peptide Antagonist of the IL-23 Receptor, in Normal Healthy Volunteers","volume":"114","author":"Cheng","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"17515","DOI":"10.1038\/s41598-024-67371-5","article-title":"JNJ-77242113, a Highly Potent, Selective Peptide Targeting the IL-23 Receptor, Provides Robust IL-23 Pathway Inhibition upon Oral Dosing in Rats and Humans","volume":"14","author":"Fourie","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_43","unstructured":"(2025, December 19). A Study Evaluating Participants with Moderately to Severely Active Crohn\u2019s Disease (PRISM), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT04102111."},{"key":"ref_44","unstructured":"Abreu, M. (2025, January 4\u20137). Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, in Moderately to Severely Active Ulcerative Colitis: Week 12 Results from the Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Treat-through, Dose-Ranging ANTHEMUC Trial. Proceedings of the United European Gastroenterology Week (UEGW), Berlin, Germany."},{"key":"ref_45","first-page":"S312","article-title":"S1449 Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, in Ulcerative Colitis: Results from Week 28 of ANTHEM-UC, a Phase 2b Dose-Ranging Trial","volume":"120","author":"Jairath","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_46","unstructured":"(2025, December 09). A Study of Icotrokinra in Participants with Moderately to Severely Active Crohn\u2019s Disease (ICONIC-CD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07196722."},{"key":"ref_47","unstructured":"(2025, December 09). A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis (ICONIC-UC), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07196748."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"jjaf080","DOI":"10.1093\/ecco-jcc\/jjaf080","article-title":"Deucravacitinib in Patients with Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results from 3 Randomized Phase 2 Studies in Crohn\u2019s Disease and Ulcerative Colitis","volume":"19","author":"Danese","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"i1853","DOI":"10.1093\/ecco-jcc\/jjae190.1175","article-title":"P1001 Efficacy and Safety of an Oral Tyrosine Kinase 2 Inhibitor VTX958 in Moderately to Severely Active Crohn\u2019s Disease: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"19","author":"Danese","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in Plaque Psoriasis: 2-Year Safety and Efficacy Results from the Phase III POETYK Trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279","volume":"66","author":"Leit","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_52","unstructured":"(2025, December 19). A Study on the Safety of TAK-279 and Whether It Can Reduce Inflammation in the Bowel of Participants with Moderately to Severely Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06233461."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ecco-jcc\/jjad212.0009","article-title":"OP09 Oral Ritlecitinib and Brepocitinib in Patients with Moderate to Severe Active Crohn\u2019s Disease: Data from the PIZZICATO Umbrella Study","volume":"18","author":"Vermeire","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ecco-jcc\/jjad212.0035","article-title":"OP35 Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients with Moderate to Severe Crohn\u2019s Disease: Results from the Phase 3 VIVID 1 Study","volume":"18","author":"Jairath","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease","volume":"391","author":"Chapman","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus Golimumab Combination Therapy versus Guselkumab or Golimumab Monotherapy in Patients with Ulcerative Colitis (VEGA): A Randomised, Double-Blind, Controlled, Phase 2, Proof-of-Concept Trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared with Adalimumab for the Continuous Treatment of Patients with Moderate to Severe Psoriasis: Results from the Phase III, Double-Blinded, Placebo- and Active Comparator\u2013Controlled VOYAGE 1 Trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"jjaf144","DOI":"10.1093\/ecco-jcc\/jjaf144","article-title":"Practical Considerations for the Use of IL-23p19 Inhibitors in Inflammatory Bowel Disease: How to Choose between Them and Why It Matters?","volume":"19","author":"Pugliano","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/apt.70295","article-title":"Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn\u2019s Disease","volume":"62","author":"Shehab","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Wang, S., Sun, H., Wang, Q., and Xiao, H. (2025). Efficacy and Safety of IL-23 P19 Inhibitors in the Treatment for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1490667"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","article-title":"Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn\u2019s Disease: A Systematic Review and Network Meta-Analysis","volume":"22","author":"Vuyyuru","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1053\/j.gastro.2025.08.032","article-title":"Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn\u2019s Disease: 2025 AGA Evidence Synthesis","volume":"169","author":"Singh","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2595874","DOI":"10.1080\/07853890.2025.2595874","article-title":"Efficacy and Safety of IL-23p19 and IL-12\/23p40 Inhibitors in Moderate-to-Severe Crohn\u2019s Disease: A Systematic Review and Network Meta-Analysis","volume":"57","author":"Kaneko","year":"2025","journal-title":"Ann. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-Analysis","volume":"23","author":"Shehab","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and Safety of Biologics and Small Molecule Drugs for Patients with Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wilkinson, I., Anderson, S., Fry, J., Julien, L.A., Neville, D., Qureshi, O., Watts, G., and Hale, G. (2021). Fc-Engineered Antibodies with Immune Effector Functions Completely Abolished. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0260954"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40265-025-02183-z","article-title":"Differentiating IL-23 Inhibitors in Crohn\u2019s Disease","volume":"85","author":"Nardone","year":"2025","journal-title":"Drugs"},{"key":"ref_68","unstructured":"(2025, December 04). TREMFYA\u00ae (Guselkumab) Medical Information. Available online: https:\/\/www.jnjmedicalconnect.com\/products\/tremfya\/medical-content\/tremfya-mechanism-of-action-and-molecular-profile#bibRef0aea3e89d8fbf44599ae1c53a1b786858."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sachen, K.L., Hammaker, D., Sarabia, I., Stoveken, B., Hartman, J., Leppard, K.L., Manieri, N.A., Bao, P., Greving, C., and Lacy, E.R. (2025). Guselkumab Binding to CD64+ IL-23\u2013Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1532852"},{"key":"ref_70","unstructured":"(2025, October 31). Omvoh, INN: Mirikizumab\u2014European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omvoh-epar-product-information_en.pdf."},{"key":"ref_71","unstructured":"(2025, October 31). Tremfya, INN\u2014Guselkumab\u2014European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tremfya-epar-product-information_en.pdf."},{"key":"ref_72","unstructured":"(2025, October 31). Skyrizi, INN\u2014Risankizumab\u2014EMA. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/skyrizi-epar-product-information_en.pdf."},{"key":"ref_73","unstructured":"(2025, October 16). SKYRIZI (Risankizumab-Rzaa) Injection, for Subcutaneous or Intravenous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761105s032lbl.pdf."},{"key":"ref_74","unstructured":"(2025, October 16). OMVOH (Mirikizumab-Mrkz) Injection for Intravenous or Subcutaneous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761279s003lbl.pdf."},{"key":"ref_75","unstructured":"(2025, October 16). TREMFYA\u00ae (Guselkumab) Injection, for Subcutaneous or Intravenous Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761061s024lbl.pdf."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"102850","DOI":"10.1016\/j.eclinm.2024.102850","article-title":"Designing for Medication Adherence in Inflammatory Bowel Disease: Multi-Disciplinary Approaches for Self-Administrable Biotherapeutics","volume":"77","author":"Feig","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000528586","article-title":"Inflammatory Bowel Disease Patients\u2019 Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study","volume":"41","author":"Khalil","year":"2023","journal-title":"Dig. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1080\/13696998.2019.1632204","article-title":"Cost per Response for Guselkumab versus Adalimumab in the United States Using Data from a Head-to-Head Trial in Moderate-to-Severe Plaque Psoriasis","volume":"22","author":"Teeple","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/ibd\/izae020.094","article-title":"Cost-Effectiveness Analysis of Mirikizumab versus Ustekinumab in Advanced Therapy Experienced Patients with Moderately to Severely Active Ulcerative Colitis in the US","volume":"30","author":"Wang","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ueg2.12720","article-title":"Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults with Inflammatory Bowel Disease: A Systematic Review","volume":"13","author":"Chen","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e00579","DOI":"10.14309\/ctg.0000000000000579","article-title":"Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities","volume":"14","author":"Bourgonje","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chom.2021.06.019","article-title":"Multi-Omics Reveal Microbial Determinants Impacting Responses to Biologic Therapies in Inflammatory Bowel Disease","volume":"29","author":"Lee","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/ecco-jcc\/jjy099","article-title":"Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients with Active Crohn\u2019s Disease: Results from a Randomised Phase II Biopsy Sub-Study","volume":"12","author":"Visvanathan","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Hoffmann, P., Lamerz, D., Hill, P., Kirchner, M., and Gauss, A. (2021). Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with Crohn\u2019s Disease: On the Way to Personalized Medicine?. Genes, 12.","DOI":"10.3390\/genes12060866"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/1744666X.2025.2461584","article-title":"Genetic Polymorphisms Impacting Clinical Pharmacology of Drugs Used to Treat Inflammatory Bowel Disease: A Precursor to Multi-Omics Approach to Precision Medicine","volume":"21","author":"Stanton","year":"2025","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.mam.2012.07.018","article-title":"Epigenetics: The Link between Nature and Nurture","volume":"34","author":"Tammen","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"171","DOI":"10.59249\/FTXB7704","article-title":"Pharmacoepigenetic Biomarkers in Inflammatory Bowel Diseases: A Narrative Review","volume":"98","author":"Servian","year":"2025","journal-title":"Yale J. Biol. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S2468-1253(25)00102-5","article-title":"Development and Validation of Peripheral Blood DNA Methylation Signatures to Predict Response to Biological Therapy in Adults with Crohn\u2019s Disease (EPIC-CD): An Epigenome-Wide Association Study","volume":"10","author":"Joustra","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/acr2.11589","article-title":"Guselkumab Modulates Differentially Expressed Genes in Blood of Patients with Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials","volume":"5","author":"Siebert","year":"2023","journal-title":"ACR Open Rheumatol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Fabian, O., Bajer, L., Drastich, P., Harant, K., Sticova, E., Daskova, N., Modos, I., Tichanek, F., and Cahova, M. (2023). A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119386"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1038\/ctg.2012.2","article-title":"Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease","volume":"3","author":"Cayatte","year":"2012","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","article-title":"Gut Microbiome Function Predicts Response to Anti-Integrin Biologic Therapy in Inflammatory Bowel Diseases","volume":"21","author":"Ananthakrishnan","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/ecco-jcc\/jjaa039","article-title":"Metabonomics and the Gut Microbiome Associated with Primary Response to Anti-TNF Therapy in Crohn\u2019s Disease","volume":"14","author":"Ding","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"127660","DOI":"10.1016\/j.micres.2024.127660","article-title":"Gut Microbiota and Metabolites as Predictors of Biologics Response in Inflammatory Bowel Disease: A Comprehensive Systematic Review","volume":"282","author":"Wang","year":"2024","journal-title":"Microbiol. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13099-024-00637-5","article-title":"Dynamic Changes in the Gut Microbiota Composition during Adalimumab Therapy in Patients with Ulcerative Colitis: Implications for Treatment Response Prediction and Therapeutic Targets","volume":"16","author":"Oh","year":"2024","journal-title":"Gut Pathog."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/ibd\/izz131","article-title":"Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease","volume":"26","author":"Fernandes","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/ibd\/izae231","article-title":"Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated with Increased Drug Persistence in Patients with Inflammatory Bowel Disease","volume":"31","author":"Porth","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_99","unstructured":"(2025, October 17). Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-Drug Antibodies of Risankizumab and the Development of a Response-Concentration Curve for Risankizumab in Patients with Psoriasis. Available online: https:\/\/clinicaltrial.be\/nl\/details\/188748?active_not_recruiting=0&completed=0&enrolling_by_invitation=0&not_yet_recruiting=0&only_eligible=0&only_recruiting=1&per_page=100&recruiting=1."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Faelens, R., Wang, Z., Bouillon, T., Declerck, P., Ferrante, M., Vermeire, S., and Dreesen, E. (2021). Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101623"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/psp4.70089","article-title":"Model-Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models","volume":"14","author":"Kim","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jid.2025.01.031","article-title":"Personalizing Biologic Therapy in Psoriasis: Development, Validation, and User Testing of a Precision-Dosing Dashboard","volume":"145","author":"Thomas","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2024.04.016","article-title":"Long-Term Outcome of Risankizumab in Crohn\u2019s Disease: A Real-World GETAID Study","volume":"22","author":"Fumery","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"jjaf070","DOI":"10.1093\/ecco-jcc\/jjaf070","article-title":"A Multicenter Study of the Real-World Effectiveness and Safety of Risankizumab in Crohn\u2019s Disease","volume":"19","author":"Johnson","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000547048","article-title":"Real-World Data on the Effectiveness of Ustekinumab and Risankizumab for Crohn\u2019s Disease","volume":"10","author":"Morikawa","year":"2025","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/PTT.S533005","article-title":"Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study","volume":"15","author":"Mortato","year":"2025","journal-title":"Psoriasis Targets Ther."},{"key":"ref_107","unstructured":"(2025, November 05). A Study to Generate Real-World Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany (GORGEOUS), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07102368?tab=results."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","article-title":"Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center","volume":"70","author":"Choi","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/apt.70140","article-title":"Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study","volume":"61","author":"Takagi","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Kubesch, A., Lande, R., Leutg\u00f6b, A., Farrag, K., Dahmer, I., Stratmann-Vollrath, K., Dienethal, A., Michael, F.A., Sprinzl, K., and Zeuzem, S. (2025). Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-Study: A Tertiary Referral Center Study on Patients with Therapy-Refractory Ulcerative Colitis. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0334897"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"S2540","DOI":"10.14309\/01.ajg.0001044944.41479.14","article-title":"S3894 Use of Risankizumab in a Patient with Recurrent Isolated Perianal Crohn\u2019s Disease Despite Total Proctocolectomy: A Case Report","volume":"119","author":"Ferrari","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_112","unstructured":"(2025, November 06). A Study of Guselkumab in Participants with Fistulizing, Perianal Crohn\u2019s Disease (FUZION CD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05347095."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and Safety of Risankizumab for Crohn\u2019s Disease in Patients from Asian Countries: A Post Hoc Subanalysis of the Global Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies","volume":"39","author":"Gao","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"i1435","DOI":"10.1093\/ecco-jcc\/jjad212.0905","article-title":"P775 Efficacy and Safety of Risankizumab in Children with Crohn\u2019s Disease: A Preliminary Report","volume":"18","author":"Spencer","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/psp4.13286","article-title":"Mirikizumab Pharmacokinetics and Exposure\u2013Response in Pediatric Patients with Moderate-to-severe Ulcerative Colitis","volume":"14","author":"Otani","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_116","unstructured":"(2025, November 06). A Study of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis (QUASAR Jr), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06260163."},{"key":"ref_117","unstructured":"(2025, November 06). A Study of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn\u2019s Disease (MACARONI-23), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05923073."},{"key":"ref_118","unstructured":"(2025, November 06). A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants with Ulcerative Colitis or Crohn\u2019s Disease (SHINE-ON) (SHINE-ON), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04844606."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S2468-1253(25)00196-7","article-title":"Efficacy and Safety of Mirikizumab in Paediatric Participants with Moderately-to-Severely Active Ulcerative Colitis (SHINE-1): A Multicentre, Open-Label, Non-Randomised Phase 2 Trial","volume":"11","author":"Kaplan","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40262-024-01370-7","article-title":"Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review","volume":"63","author":"Emaus","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/ibd\/izae182","article-title":"Low Placental Transfer Rates of Risankizumab Among Pregnant Women with Inflammatory Bowel Disease","volume":"30","author":"Mahadevan","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Tsur, N., Ben Ya\u2019acov, A., Ungar, B., Ron, Y., Avni-Biron, I., Reiss Mintz, H., Koslowsky, B., Mishael, T., and Bar Gil Shitrit, A. (2025). Safety of Risankizumab during Pregnancy in IBD. Inflamm. Bowel Dis., izaf305.","DOI":"10.1093\/ibd\/izaf305"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.crphar.2022.100104","article-title":"Positioning Biologics in the Treatment of IBD: A Practical Guide\u2014Which Mechanism of Action for Whom?","volume":"3","author":"Juillerat","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"105922","DOI":"10.1016\/j.jbspin.2025.105922","article-title":"Advanced Combination Therapy in Inflammatory Bowel Disease","volume":"92","author":"Morizot","year":"2025","journal-title":"Jt. Bone Spine"},{"key":"ref_125","unstructured":"(2025, November 19). A Study of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis (DUET-UC), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05242484."},{"key":"ref_126","unstructured":"(2025, November 19). A Study of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn\u2019s Disease (DUET-CD), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05242471."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:50:26Z","timestamp":1771231826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":126,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jpm16020119"],"URL":"https:\/\/doi.org\/10.3390\/jpm16020119","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]}}}